Verastem, Inc. (VSTM) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Verisim Oncology's third quarter 2025 earnings conference call. My name is Liz and I'll be your call operator for today. Please note this event is being recorded. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. I will now turn the call over to Julissa Vianna, Vice President of Corporate Communications, Investor Relations, and Patient Advocacy at Verisim Oncology. Please go ahead. Thank you, Operator. Welcome, everyone, and thank you for joining us today to discuss Verisim's third quarter 2025 financial results and recent business updates. This morning, we issued a press release detailing our financial results for the quarter and year to date. This release, along with the slide presentation that we will reference during our call today, are available on our website. Before we begin, I would like to remind you that any statements made during this call are not historical and are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the risk factors section in the company's most recent annual report on Form 10-K, filed with the SEC on March 20, 2025, and the current report on Form 10-Q that will be filed later today, as well as other reports filed with the SEC. Any forward-looking statements we make represent Verisim's views as of today, and we disclaim any obligations or responsibilities to update. Joining me on today's call are Dan Patterson, President and Chief Executive Officer of Veristem, who will provide opening remarks and recap key highlights from the...